Yes is a central mediator of cell growth in malignant mesothelioma cells

Sato,Ayami; Sekine,Miki; Virgona,Nantiga; Ota,Masako; Yano,Tomohiro

doi:10.3892/or.2012.2010

Yes is a central mediator of cell growth in malignant mesothelioma cells

Authors:
- Ayami Sato
- Miki Sekine
- Nantiga Virgona
- Masako Ota
- Tomohiro Yano
View Affiliations

Affiliations: Faculty of Life Sciences, Toyo University, Itakura, Oura, Gunma 374-0193, Japan
Published online on: September 3, 2012 https://doi.org/10.3892/or.2012.2010
Pages: 1889-1893

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The constitutive activation of the Src family kinases (SFKs) has been established as a poor prognostic factor in malignant mesothelioma (MM), however, the family member(s) which contribute to the malignancy have not been defined. This study aimed to identify the SFK member(s) contributing to cell growth using RNA interference in various MM cell lines. Silencing of Yes but not of c-Src or Fyn in MM cells leads to cell growth suppression. This suppressive effect caused by Yes silencing mainly depends on G1 cell cycle arrest and partly the induction of apoptosis. Also, the knockout of Yes induces the inactivation of β-catenin signaling and subsequently decreases the levels of cyclin D necessary for G1-S transition in the cell cycle. In addition, Yes knockout has less effect on cell growth suppression in β-catenin-deficient H28 MM cells compared to other MM cells which express the catenin. Overall, we conclude that Yes is a central mediator for MM cell growth that is not shared with other SFKs such as c-Src.

View Figures

View References

1	Carbone M, Kratzke RA and Testa JR: The pathogenesis of mesothelioma. Semin Oncol. 29:2–17. 2002. View Article : Google Scholar
2	Nowak AK, Lake RA, Kindler HL and Robinson BW: New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol. 29:82–96. 2002. View Article : Google Scholar : PubMed/NCBI
3	Tomek S, Emri S, Krejcy K and Manegold C: Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Br J Cancer. 88:167–174. 2003. View Article : Google Scholar : PubMed/NCBI
4	Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
5	Takeuchi K and Ito F: Receptor tyrosine kinases and targeted cancer therapeutics. Biol Pharm Bull. 34:1774–1780. 2011. View Article : Google Scholar : PubMed/NCBI
6	Benati D and Baldari CT: SRC family kinases as potential therapeutic targets for malignancies and immunological disorders. Curr Med Chem. 15:1154–1165. 2008. View Article : Google Scholar : PubMed/NCBI
7	Sen B and Johnson FM: Regulation of Src family kinases in human cancers. J Signal Transduct. 2011:1–14. 2011. View Article : Google Scholar
8	Thomas SM and Brugge JS: Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 13:513–609. 1997. View Article : Google Scholar : PubMed/NCBI
9	Ishizawar R and Parsons SJ: C-Src and cooperating partners in human cancer. Cancer Cell. 6:209–214. 2004. View Article : Google Scholar : PubMed/NCBI
10	Abram CL and Courteidge: Src family tyrosine kinases and growth factor signaling. Exp Cell Res. 254:1–13. 2000. View Article : Google Scholar : PubMed/NCBI
11	Roche S and Courtneidge SA: v-Yes as a transforming factor. Oncogenic Cytoplasmic Tyrosine Kinases. Peters G and Vousden KH: Oxford University Press; Oxford; pp. 87–120. 1997
12	Pena SV, Melhem MF, Meisler AI and Cartwright CA: Elevated c-Yes tyrosine kinase activity in premalignant lesions of the colon. Gastroenterology. 108:117–124. 1995. View Article : Google Scholar : PubMed/NCBI
13	Han NM, Curley SA and Gallick GE: Differential activation of pp60(c-src) and pp62(c-yes) in human colorectal carcinoma liver metastases. Clin Cancer Res. 2:1397–1404. 1996.PubMed/NCBI
14	Kashiwagi K, Harada K, Yano Y, et al: A redox-silent analogue of tocotrienol inhibits hypoxia adaptation of lung cancer cells. Biochem Biophys Res Commun. 365:875–881. 2008. View Article : Google Scholar : PubMed/NCBI
15	Tsao AS, He D, Saigal B, et al: Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther. 6:1962–1972. 2007. View Article : Google Scholar : PubMed/NCBI
16	Sancier F, Dumont A, Sirvent A, et al: Specific oncogenic activity of the Src-family tyrosine kinase c-Yes in colon carcinoma cells. Plos One. 6:1–10. 2011. View Article : Google Scholar : PubMed/NCBI
17	Kato-Stankiewicz J, Hakimi I, Zhi G, et al: Inhibitors of Ras/Raf-1 interaction identified by two hybrid screening revert Ras-dependent transformation phenotypes in human cnacer cells. Proc Natl Acad Sci USA. 99:14398–14403. 2002. View Article : Google Scholar : PubMed/NCBI
18	Kim YM, Ma H, Oehler VG, et al: The gamma catenin/CBP complex maintains survivin transcription in β-catenin deficient/depleted cancer cells. Curr Cancer Drug Targets. 11:213–225. 2011.PubMed/NCBI
19	Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 15:493–500. 2003.PubMed/NCBI
20	Kao SC, Lee K, Armstrong NJ, et al: Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology. 43:128–132. 2011. View Article : Google Scholar : PubMed/NCBI
21	Johnson FM, Saigal B, Tran H and Donato NJ: Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res. 13:4233–4244. 2007. View Article : Google Scholar
22	Menges CW, Chen Y, Mossman BT, et al: A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma. Genes Cancer. 1:493–505. 2010. View Article : Google Scholar
23	Kashiwagi K, Virgona N, Harada K, et al: A redox-silent analogue of tocotrienol acts as a potential cytotoxic agent against human mesothelioma cells. Life Sci. 84:650–656. 2009. View Article : Google Scholar : PubMed/NCBI
24	Cadigan KM: TCFs and Wnt/β-catenin signaling: more than one way to throw the switch. Curr Top Dev Biol. 98:1–34. 2012.
25	Saini SS and Klein MA: Targeting cyclin D1 in non-small cell lung cancer and mesothelioma cells by antisense oligonucleotides. Anticancer Res. 31:3683–3690. 2011.PubMed/NCBI
26	Oneyama C, Ichino T, Saito K, et al: Transforming potential of Src family kinases is limited by the cholesterol-enriched membrane microdomain. Mol Cell Biol. 29:6462–6472. 2009. View Article : Google Scholar : PubMed/NCBI